SCHEMBL19205946

SCHEMBL19205946

O=C(Nc1cc(Cl)ccc1OP(=O)(O)O)c1cccc(S(=O)(=O)C2CCCCC2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPM1D O15297 3/20 0.45
RAB9A P51151 3/20 0.45
ALDH1A1 P00352 2/20 0.45
NPC1 O15118 2/20 0.45
LMNA P02545 1/20 0.45
SERPINE1 P05121 1/20 0.43
MAPT P10636 1/20 0.42
PPARG P37231 3/20 0.41
PPARD Q03181 3/20 0.41
PPARA Q07869 3/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
USP2 O75604 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
KCNMA1 Q12791 1/20 0.41
ATM Q13315 2/20 0.41
ALB P02768 1/20 0.40
MAPK1 P28482 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17479362 0.93 PPM1D (0.42) PPM1DRAB9AALDH1A1NPC1LMNA
SCHEMBL17479118 0.88 POLB (0.44) PPM1DALDH1A1LMNAMAPTKMT2A
SCHEMBL17479304 0.83 MEN1 (0.60) RAB9AALDH1A1NPC1MAPTKMT2A
SCHEMBL19205938 0.76 MEN1 (0.61) RAB9AALDH1A1NPC1MAPTKMT2A
SCHEMBL1001298 0.76 ALDH1A1 (0.53) RAB9AALDH1A1NPC1LMNAMAPT
SCHEMBL16903002 0.73 SMN1; SMN2 (0.62) RAB9AALDH1A1NPC1LMNAMAPT
SCHEMBL17128989 0.71 HTR2B (0.63) RAB9AALDH1A1NPC1MAPTKMT2A
SCHEMBL2565722 0.70 AKR1C3 (0.51) ALDH1A1LMNAMAPTKMT2AMEN1
SCHEMBL1001949 0.70 MEN1 (0.67) RAB9AALDH1A1NPC1LMNAMAPT
SCHEMBL28004741 0.70 SMN1; SMN2 (0.55) RAB9AALDH1A1NPC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 EP disclosed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 US disclosed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS FLT3, CSF1R, CSF3R PPM1D 906/4885RAB9A 3802/4885ALDH1A1 2419/4885
US-10065937-B2 FLT3 receptor antagonists FLT3, CSF1R, CSF3R PPM1D 906/4885RAB9A 3802/4885ALDH1A1 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.